Grail’s Cancer Test Faces Its Most Important Question Yet

An FDA panel is reviewing Grail’s Galleri cancer blood test today. Its view on whether the evidence supports “early detection” could prove as important as its overall recommendation.

Grail’s Galleri blood test is designed to look for signals from more than 50 types of cancer. Today, an FDA advisory panel is reviewing the company’s application for approval. The question goes beyond whether the test can find cancer: does the evidence support calling it an early-detection test?

That distinction matters to patients, doctors and investors. Detecting a cancer signal is valuable only if it leads to useful care; finding cancers earlier is central to Grail’s case for broader use.

Why the wording matters

FDA staff have asked the panel to examine how Galleri performs across cancer types and stages, and whether the results justify the word “early” in its proposed use. They have also asked advisers to consider a description without that word if the evidence does not support it.

The review comes with a significant complication. In a large UK trial, routine use of Galleri did not significantly improve early detection or reduce late-stage cancer diagnoses across the trial’s main measures, according to Reuters. The test is already available in the US through a laboratory pathway, but it does not have FDA approval.

The panel’s recommendation will be an important signal, though the FDA makes the final approval decision. Investors should watch both what the panel recommends and what claims it believes Galleri can support. Those details will shape how Grail can present the test to doctors and patients.